CLOFAZIMINE

July 1, 2022

Clofazimine, a key drug for treatment of leprosy, which had been in short supply in the Indian market for several months, is now “not available”, with the situation turning into a crisis over the past three months.

About:

Clofazimine is one of the three essential drugs in the Multi Drug Treatment of Multibacillary Leprosy (MB-MDT) cases, along with Rifampicin and Dapsone.
According to the World Health Organization (WHO), leprosy is endemic in several States and Union Territories of India, with the annual case detection rate of 4.56 per 10,000 population.
The prevalence rate of leprosy is 0.4 per 10,000 population in the country.
Of the new cases detected during 2020-21, 58.1% were multibacillary, 39% were women, 5.8% were children less than 14 years of age, and 2.41% had visible deformities. The rate of visible deformities was 1.1 per million population.

Source : The Hindu